{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T01:52:03Z","timestamp":1780624323452,"version":"3.54.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Dopamine-replacement utilizing L-DOPA is still the mainstay treatment for Parkinson\u2019s disease (PD), but often leads to development of L-DOPA-induced dyskinesia (LID), which can be as debilitating as the motor deficits. There is currently no satisfactory pharmacological adjunct therapy. The endogenous opioid peptides enkephalin and dynorphin are important co-transmitters in the direct and indirect striatofugal pathways and have been implicated in genesis and expression of LID. Opioid receptor antagonists and agonists with different selectivity profiles have been investigated for anti-dyskinetic potential in preclinical models. In this study we investigated effects of the highly-selective \u03bc-opioid receptor antagonist CTAP (&gt;\u20091200-fold selectivity for \u03bc- over \u03b4-opioid receptors) and a novel glycopeptide congener (gCTAP5) that was glycosylated to increase stability, in the standard rat LID model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Intraperitoneal administration (\n                      <jats:italic>i.p.<\/jats:italic>\n                      ) of either 0.5\u00a0mg\/kg or 1\u00a0mg\/kg CTAP and gCTAP5 completely blocked morphine\u2019s antinociceptive effect (10\u00a0mg\/kg;\n                      <jats:italic>i.p.<\/jats:italic>\n                      ) in the warm water tail-flick test, showing in vivo activity in rats after systemic injection. Neither treatment with CTAP (10\u00a0mg\/kg;\n                      <jats:italic>i.p.<\/jats:italic>\n                      ), nor gCTAP5 (5\u00a0mg\/kg;\n                      <jats:italic>i.p.<\/jats:italic>\n                      ) had any effect on L-DOPA-induced limb, axial, orolingual, or locomotor abnormal involuntary movements. The data indicate that highly-selective \u03bc-opioid receptor antagonism alone might not be sufficient to be anti-dyskinetic.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13104-020-04994-7","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T07:03:21Z","timestamp":1583996601000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Highly-selective \u00b5-opioid receptor antagonism does not block L-DOPA-induced dyskinesia in a rodent model"],"prefix":"10.1186","volume":"13","author":[{"given":"Mitchell J.","family":"Bartlett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa Y.","family":"So","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lajos","family":"Szab\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Skinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate L.","family":"Parent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Heien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd W.","family":"Vanderah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Polt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Falk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,12]]},"reference":[{"key":"4994_CR1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1212\/WNL.0b013e3181a1d44c","volume":"72","author":"CW Olanow","year":"2009","unstructured":"Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology. 2009;72:S1\u2013136.","journal-title":"Neurology"},{"key":"4994_CR2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1124\/pr.111.005678","volume":"65","author":"P Huot","year":"2013","unstructured":"Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM. The pharmacology of L-DOPA-induced dyskinesia in Parkinson\u2019s disease. Pharmacol Rev. 2013;65:171\u2013222.","journal-title":"Pharmacol Rev"},{"key":"4994_CR3","doi-asserted-by":"publisher","first-page":"10814","DOI":"10.1523\/JNEUROSCI.2660-08.2008","volume":"28","author":"TS Gertler","year":"2008","unstructured":"Gertler TS, Chan CS, Surmeier DJ. Dichotomous anatomical properties of adult striatal medium spiny neurons. J Neurosci. 2008;28:10814\u201324.","journal-title":"J Neurosci"},{"key":"4994_CR4","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1471-4159.1984.tb02698.x","volume":"42","author":"BR Seizinger","year":"1984","unstructured":"Seizinger BR, Grimm C, H\u00f6llt V, Herz A. Evidence for a selective processing of proenkephalin B into different opioid peptide forms in particular regions of rat brain and pituitary. J Neurochem. 1984;42:447\u201357.","journal-title":"J Neurochem"},{"key":"4994_CR5","doi-asserted-by":"crossref","first-page":"27084","DOI":"10.1016\/S0021-9258(19)74221-5","volume":"268","author":"MB Breslin","year":"1993","unstructured":"Breslin MB, Lindberg I, Benjannet S, Mathis JP, Lazure C, Seidah NG. Differential processing of proenkephalin by prohormone convertases 1(3) and 2 and furin. J Biol Chem. 1993;268:27084\u201393.","journal-title":"J Biol Chem"},{"key":"4994_CR6","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nn.3652","volume":"17","author":"BK Atwood","year":"2014","unstructured":"Atwood BK, Kupferschmidt DA, Lovinger DM. Opioids induce dissociable forms of long-term depression of excitatory inputs to the dorsal striatum. Nat Neurosci. 2014;17:540\u20138.","journal-title":"Nat Neurosci"},{"key":"4994_CR7","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1002\/mds.23631","volume":"26","author":"JB Koprich","year":"2011","unstructured":"Koprich JB, Fox SH, Johnston TH, Goodman A, Bourdonnec B, Dolle RE, DeHaven RN, DeHaven-Hudkins DL, Little PJ, Brotchie JM. The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson\u2019s disease. Mov Disord. 2011;26:1225\u201333.","journal-title":"Mov Disord"},{"key":"4994_CR8","first-page":"402","volume":"280","author":"TJ Abbruscato","year":"1997","unstructured":"Abbruscato TJ, Thomas S, Hruby VJ, Davis TP. Blood-brain barrier permeability and bioavailability of a highly potent and mu-selective opioid receptor antagonist, CTAP: comparison with morphine. J Pharmacol Exp Ther. 1997;280:402\u20139.","journal-title":"J Pharmacol Exp Ther"},{"key":"4994_CR9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3389\/fchem.2015.00040","volume":"3","author":"EM Jones","year":"2015","unstructured":"Jones EM, Polt R. CNS active O-linked glycopeptides. Front Chem. 2015;3:40.","journal-title":"Front Chem"},{"key":"4994_CR10","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1021\/jo005712m","volume":"66","author":"SA Mitchell","year":"2001","unstructured":"Mitchell SA, Pratt MR, Hruby VJ, Polt R. Solid-phase synthesis of O-linked glycopeptide analogues of encephalin. J Org Chem. 2001;66:2327\u201342.","journal-title":"J Org Chem"},{"key":"4994_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.neulet.2015.11.047","volume":"612","author":"MJ Bartlett","year":"2016","unstructured":"Bartlett MJ, Joseph RM, LePoidevin LM, Parent KL, Laude ND, Lazarus LB, Heien ML, Estevez M, Sherman SJ, Falk T. Long-term effect of sub-anesthetic ketamine in reducing L-DOPA-induced dyskinesias in a preclinical model. Neurosci Lett. 2016;612:121\u20135.","journal-title":"Neurosci Lett"},{"key":"4994_CR12","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.neuropharm.2018.09.005","volume":"141","author":"AJ Flores","year":"2018","unstructured":"Flores AJ, Bartlett MJ, Root BK, Parent KL, Heien ML, Porreca F, Polt R, Sherman SJ, Falk T. The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia. Neuropharmacology. 2018;141:260\u201371.","journal-title":"Neuropharmacology"},{"key":"4994_CR13","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.neuropharm.2017.11.046","volume":"131","author":"TH Johnston","year":"2018","unstructured":"Johnston TH, Versi E, Howson PA, Ravenscroft P, Fox SH, Hill MP, Reidenberg BE, Corey R, Brotchie JM. DPI-289, a novel mixed delta opioid agonist\/mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson\u2019s disease. Neuropharmacology. 2018;131:116\u201327.","journal-title":"Neuropharmacology"},{"key":"4994_CR14","first-page":"930","volume":"77","author":"LF Potts","year":"2015","unstructured":"Potts LF, Park ES, Woo JM, Dyavar Shetty BL, Singh A, Braithwaite SP, Voronkov M, Papa SM, Mouradian MM. Dual \u03ba-agonist\/\u03bc-antagonist opioid receptor modulation reduces levodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson\u2019s disease. Neurology. 2015;77:930\u201341.","journal-title":"Neurology"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-020-04994-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13104-020-04994-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-020-04994-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T20:04:25Z","timestamp":1615493065000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-020-04994-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,12]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4994"],"URL":"https:\/\/doi.org\/10.1186\/s13104-020-04994-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.21906\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.21906\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.21906\/v2","asserted-by":"object"}]},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,12]]},"assertion":[{"value":"21 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animals were treated as approved by the Institutional Animal Care and Use Committee at the University of Arizona and in accordance with the NIH Guidelines for the Care and Use of Laboratory Animals.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"149"}}